POOLBEG PHARMA PLC - POLBF STOCK NEWS

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) has announced its consortium, EncOVac, has secured €2.3 million in non-dilutive funding from the Irish Government's Disruptive Technologies Innovation Fund. The funding will support the development of an oral vaccine platform over a three-year period, aiming for a Phase I ready state. The collaboration includes partners from University College Dublin, Trinity College Dublin, and AnaBio Technologies. This initiative could lead to advancements in oral vaccine technologies, addressing challenges in vaccine administration and distribution.

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) has achieved a milestone in its AI programme, identifying novel drug targets to treat Respiratory Syncytial Virus (RSV) in collaboration with OneThree Biotech. This breakthrough, utilizing tailored AI models and unique human challenge trial data, accelerates the transition to identifying small molecule inhibitors for RSV. The final research stage, expected to yield results by the end of 2022, aims to pinpoint effective drug candidates with existing Phase I data, streamlining the drug discovery process significantly.

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), a clinical stage infectious disease pharmaceutical company, announced CEO Jeremy Skillington purchased 718,733 ordinary shares at 4.78 pence each on October 5, 2022. This acquisition represents 0.14% of the total issued share capital. Skillington expressed confidence in the company’s potential for value creation as it progresses with its pipeline of infectious disease treatments. The announcement is considered inside information under market regulations.

Poolbeg Pharma updates on its intellectual property (IP) expansion for POLB 001, an immunomodulator targeting severe influenza. The US Patent and Trademarks Office has indicated the main claim for POLB 001's use in treating hypercytokinemia is allowable, with a formal patent grant anticipated. The company also holds worldwide licensing rights and aims to broaden its IP to enhance asset value for potential partnerships. Existing patents protect severe influenza treatment until at least 2037. CEO Jeremy Skillington expresses optimism about increased product value and upcoming trial results.

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) has signed a License Agreement with University College Dublin for a preclinical vaccine candidate for Melioidosis, a high-mortality infectious disease. This vaccine candidate, known as POLB 003, is significant as there is currently no approved vaccine for this disease, which sees rising cases due to climate change. The collaboration aims to expedite the development of POLB 003, leveraging Poolbeg's expertise in infectious diseases. The global need for effective vaccines against this biothreat underlines the commercial potential of this partnership.

Poolbeg Pharma (AIM:POLB, OTCQB:POLBF) announced that its Chairman, Cathal Friel, will attend the HC Wainwright Global Investment Conference in New York City from September 12-14, 2022. The company, a clinical stage infectious disease pharmaceutical firm, aims to develop products faster and more cost-effectively than traditional biotech models. Poolbeg targets the growing infectious disease market, projected to exceed $250bn by 2025, with key assets including a small molecule immunomodulator and an RNA-based immunotherapy.

Poolbeg Pharma has appointed Singer Capital Markets as its Joint Broker, effective immediately. This addition complements existing collaborations with finnCap Ltd and J&E Davy. Poolbeg, a clinical-stage pharmaceutical company focused on infectious diseases, aims to advance multiple products efficiently. With a market expected to exceed $250 billion by 2025, Poolbeg utilizes insights from Open Orphan plc to enhance asset acquisition and clinical positioning, including several promising products in its pipeline.

Poolbeg Pharma has received regulatory approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, aimed at treating severe influenza. The trial, starting on July 22, 2022, will evaluate POLB 001’s efficacy in dampening hyperinflammatory responses. Initial results are anticipated in Q4 2022, with plans for rapid monetization through partnerships. The treatment's strain-agnostic nature could potentially expand its applications beyond influenza, positioning it as a valuable asset for both patients and shareholders.

Poolbeg Pharma announces the successful completion of the AI model for analyzing Respiratory Syncytial Virus (RSV) data, a first in utilizing AI with complete longitudinal data. This collaboration with OneThree Biotech aims to identify novel drug targets and potential treatments more efficiently. The results of the analysis are expected in Q4 2022. This AI model will leverage unique data derived from human challenge trials, contributing to Poolbeg's goal of addressing the significant public health threat posed by RSV, which results in an estimated 100,000 deaths in children under five annually.